A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Silmitasertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker
- 24 Sep 2010 Trial initiation date reported as 24 Sep 2010 in a Cylene Pharmaceuticals media release.
- 22 Sep 2010 New trial record